Compound S1 (antidiabetic agent 5) is an antidiabetic agent that effectively inhibits the enzymes α-glucosidase and α-amylase, demonstrating IC50 values of 3.91 µM and 8.89 µM, respectively. It reduces sugar levels and holds potential for type-II diabetes research [1].

The antidiabetic agent 5 (3.9, 7.8 mg/kg) effectively lowers blood glucose levels in diabetic BALB/c mice (26-33 g) [1]. Administration at 3.9 and 7.8 mg/kg resulted in reduced blood sugar levels (110–115 mg/dL), increased insulin levels (25–30 μM/L), as well as decreased cholesterol (85 mg/dL) and creatinine (0.6 mg/dL) levels [1].